Literature DB >> 36165919

A whole blood microsampling furosemide assay: development, validation and use in a pediatric pharmacokinetic study.

Nicolas A Bamat1,2,3, Christina Vedar1, Megan E Reilly2, Ganesh S Moorthy1,4, Athena F Zuppa1,4.   

Abstract

Background: Furosemide is a commonly used diuretic for the treatment of edema. The pharmacokinetics of furosemide in neonates as they mature remains poorly understood. Microsampling assays facilitate research in pediatric populations.
Results: We developed and validated a liquid chromatography-tandem mass spectrometry method for the quantitation of furosemide in human whole blood with volumetric absorptive microsampling (VAMS) devices (10 μl). Furosemide was stable in human whole blood VAMS under the study's assay conditions. This work established stability for furosemide for 161 days when stored as dried microsamples at -78°C.
Conclusion: This method is being applied for the quantitation of furosemide in whole blood VAMS in an ongoing prospective pediatric clinical study. Representative clinical data are reported.

Entities:  

Keywords:  LC-MS/MS; furosemide; human whole blood; pediatrics; pharmacokinetics; volumetric absorptive microsampling

Mesh:

Substances:

Year:  2022        PMID: 36165919      PMCID: PMC9540403          DOI: 10.4155/bio-2022-0063

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.695


  27 in total

1.  Changes in body water compartments with diuretic therapy in infants with chronic lung disease.

Authors:  J L Segar; S Chemtob; E F Bell
Journal:  Early Hum Dev       Date:  1997-04-25       Impact factor: 2.079

Review 2.  Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease.

Authors:  Audra Stewart; Luc P Brion
Journal:  Cochrane Database Syst Rev       Date:  2011-09-07

3.  Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia.

Authors:  W H Northway; R C Rosan; D Y Porter
Journal:  N Engl J Med       Date:  1967-02-16       Impact factor: 91.245

4.  Pharmacokinetic disposition and protein binding of furosemide in newborn infants.

Authors:  J V Aranda; J Perez; D S Sitar; J Collinage; A Portuguez-Malavasi; B Duffy; C Dupont
Journal:  J Pediatr       Date:  1978-09       Impact factor: 4.406

5.  Pharmacokinetics of furosemide in neonates.

Authors:  P Vert; M Broquaire; M Legagneur; P L Morselli
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Metabolism and renal elimination of furosemide in the newborn infant.

Authors:  J V Aranda; C Lambert; J Perez; T Turmen; D S Sitar
Journal:  J Pediatr       Date:  1982-11       Impact factor: 4.406

7.  Prevalence of polypharmacy exposure among hospitalized children in the United States.

Authors:  Chris Feudtner; Dingwei Dai; Kari R Hexem; Xianqun Luan; Talene A Metjian
Journal:  Arch Pediatr Adolesc Med       Date:  2011-09-05

8.  Pharmacology of furosemide in the premature newborn infant.

Authors:  R G Peterson; M A Simmons; B H Rumack; R L Levine; J G Brooks
Journal:  J Pediatr       Date:  1980-07       Impact factor: 4.406

9.  Clinical pharmacology of furosemide in neonates: a review.

Authors:  Gian Maria Pacifici
Journal:  Pharmaceuticals (Basel)       Date:  2013-09-05

10.  Evaluation of the dose-related concentration approach in therapeutic drug monitoring of diuretics and β-blockers - drug classes with low adherence in antihypertensive therapy.

Authors:  Sabrina Ritscher; Milena Hoyer; Cora Wunder; Nicholas Obermüller; Stefan W Toennes
Journal:  Sci Rep       Date:  2019-10-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.